A prestigious invitation to chair an educational program session at the annual meeting of the American Society of Hematology (ASH) in December 2023 offered University of Colorado Cancer Center member Manali Kamdar, MD, an opportunity to update the profession about two increasingly common treatments for relapsed lymphomas.
Patient Care Community Immunotherapy lymphoma ColoradoSPH at CU Anschutz
For a significant portion of his career, Arnold Levinson, PhD, MJ, has done work related to cancer.
Research Blood Cancer Immunotherapy lymphoma
For 30% to 40% of lymphoma patients who receive CAR T therapy, the treatment is a godsend. Typically given to lymphoma patients for whom other treatments have proven ineffective, CAR T therapy involves removing immune cells from the body via a blood draw, reengineering them to become better cancer fighters, then reintroducing them to the bloodstream, where they seek out and destroy cancer cells.
Research Immunotherapy lymphoma
Large B-cell lymphoma (LBCL) is one of the most aggressive lymphomas and accounts for about 30% of all lymphoma diagnoses.
Gripped
March 27, 2024
Just 18 months after his leukemia diagnosis and on the brink of a bone marrow transplant, Chen defied the odds with an inspiring ascent. Reflecting on his journey, Chen's resilience shines through as he remains optimistic and determined for the future.
EurekAlert
March 06, 2024
Researchers at the University of Colorado Anschutz Medical Campus found that drugs like botox may slow head and neck cancer progression by targeting nerve interactions in tumor environments, impacting immune responses. This study could lead to new treatments for patients intolerant to traditional therapies.
Mile High Magazine
February 25, 2024
Christopher Lieu, MD speaks on March being Colorectal Cancer Awareness Month and the importance of screening.
National Institutes of Health (NIH)
February 21, 2024
In 2024, the network will launch a pilot study, known as the Vanguard Study on Multi-Cancer Detection, to address the feasibility of using multi-cancer detection (MCD) tests in future randomized controlled trials.
Greg Glasgow
